Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nautilus Biotechnology Inc (NAUT)

Nautilus Biotechnology Inc (NAUT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 281,263
  • Shares Outstanding, K 125,564
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,680 K
  • EBIT $ -82 M
  • EBITDA $ -78 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.34

Options Overview Details

View History
  • Implied Volatility 208.55% ( +155.42%)
  • Historical Volatility 62.63%
  • IV Percentile 86%
  • IV Rank 33.71%
  • IV High 597.35% on 04/18/24
  • IV Low 10.83% on 05/13/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 50
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 185
  • Open Int (30-Day) 173

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.16
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +4.07%
on 11/26/24
2.92 -21.18%
on 11/07/24
-0.39 (-14.50%)
since 10/25/24
3-Month
2.21 +4.07%
on 11/26/24
3.09 -25.57%
on 09/23/24
-0.34 (-12.88%)
since 08/27/24
52-Week
2.19 +5.02%
on 06/24/24
3.45 -33.42%
on 12/27/23
-0.57 (-19.86%)
since 11/27/23

Most Recent Stories

More News
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology Reports Second Quarter 2022 Financial Results

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome...

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022

SEATTLE, July 13, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein...

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology Reports First Quarter 2022 Financial Results

SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome...

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein...

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology to Present at EuPA and AACR Meetings

• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of the European Proteomics Association (EuPA) • Associate...

NAUT : 2.30 (+2.68%)
Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors

Schrödinger President of R&D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing platform for...

NAUT : 2.30 (+2.68%)

Business Summary

Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus Biotechnology Inc., formerly known as Arya Sciences Acquisition Corp III, is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 2.50
2nd Resistance Point 2.44
1st Resistance Point 2.37
Last Price 2.30
1st Support Level 2.24
2nd Support Level 2.18
3rd Support Level 2.11

See More

52-Week High 3.45
Fibonacci 61.8% 2.97
Fibonacci 50% 2.82
Fibonacci 38.2% 2.67
Last Price 2.30
52-Week Low 2.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar